Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

923
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
923
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

450
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
450
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

502
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
502
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

2.3K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.3K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

546
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
546
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

793
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
793

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Adulthood Outcomes Among Individuals With Neurologic Impairment and Technology Assistance.

Pediatrics·2026
Same author

The Role of Telemedicine on Interhospital Transfer Outcomes : A Systematic Review.

Annals of internal medicine·2026
Same author

Precision for all children: embedding equity into precision medicine for children.

BMJ paediatrics open·2026
Same author

Virtual Care Remuneration Policy and Postdischarge Follow-Up Trends.

JAMA network open·2026
Same author

Digital Health Monitoring and Intervention Suite for Stress in Frontline Nurses: Prospective Cohort Trial.

JMIR formative research·2026
Same author

SARS-CoV-2 Infection and Rates of Neonatal Congenital Anomalies.

JAMA network open·2026

Related Experiment Video

Updated: Oct 13, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.7K

Reviewing the Evidence on Prenatal Opioid Exposure to Inform Child Development Policy and Practice.

Andi Camden1, Madeleine Harris2, Sophia den Otter-Moore3

  • 1An epidemiologist and PhD candidate in the Epidemiology Division of the Dalla Lana School of Public Health at the University of Toronto and a research trainee at The Hospital for Sick Children in Toronto, ON.

Healthcare Quarterly (Toronto, Ont.)
|November 18, 2021
PubMed
Summary

Prenatal opioid exposure impacts child development, with no clear Ontario guidelines. Enhanced screening and integrated services are needed for affected children.

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

394
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.9K

Related Experiment Videos

Last Updated: Oct 13, 2025

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

86.7K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

394
Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.9K

Area of Science:

  • Public Health
  • Pediatrics
  • Neonatology

Background:

  • Prenatal opioid use is a growing concern with significant risks to maternal and child well-being.
  • Ontario currently lacks standardized guidelines and universal programs for children exposed to opioids prenatally.
  • This gap affects the healthy development and long-term outcomes for these children.

Purpose of the Study:

  • To examine the epidemiology of prenatal opioid exposure in Ontario.
  • To review child health outcomes, particularly developmental impacts, associated with prenatal opioid exposure.
  • To identify and evaluate emerging guidelines and programs for surveillance and support.

Main Methods:

  • Epidemiological analysis of prenatal opioid exposure data in Ontario.
  • Systematic review of research on child health and developmental outcomes.
  • Assessment of current and proposed guidelines for developmental surveillance.
  • Evaluation of existing and proposed support programs for affected children and families.

Main Results:

  • Data on the prevalence and trends of prenatal opioid exposure in Ontario.
  • Evidence linking prenatal opioid exposure to various child health and developmental challenges.
  • Identification of gaps in current surveillance and screening practices.
  • Overview of promising but often fragmented support programs.

Conclusions:

  • There is a critical need for enhanced developmental and vision screening for children with prenatal opioid exposure.
  • Strengthening Canadian recommendations and ensuring funding for integrated, evidence-based maternal and child services is essential.
  • A comprehensive, coordinated approach is required to support the healthy development of these vulnerable children.